CL2016001368A1 - Inhibidores de cinasa serina/treonina - Google Patents
Inhibidores de cinasa serina/treoninaInfo
- Publication number
- CL2016001368A1 CL2016001368A1 CL2016001368A CL2016001368A CL2016001368A1 CL 2016001368 A1 CL2016001368 A1 CL 2016001368A1 CL 2016001368 A CL2016001368 A CL 2016001368A CL 2016001368 A CL2016001368 A CL 2016001368A CL 2016001368 A1 CL2016001368 A1 CL 2016001368A1
- Authority
- CL
- Chile
- Prior art keywords
- serine
- kinase inhibitors
- threonine kinase
- cancer
- mielogen
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 title 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 title 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- -1 QUINAZOLIN-PYRIMIDIN-AMINE Chemical compound 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 108010032806 molgramostim Proteins 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361912905P | 2013-12-06 | 2013-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001368A1 true CL2016001368A1 (es) | 2016-12-09 |
Family
ID=52350292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001368A CL2016001368A1 (es) | 2013-12-06 | 2016-06-03 | Inhibidores de cinasa serina/treonina |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US9867833B2 (OSRAM) |
| EP (1) | EP3077401B1 (OSRAM) |
| JP (2) | JP6449293B2 (OSRAM) |
| KR (1) | KR102359759B1 (OSRAM) |
| CN (1) | CN106029672B (OSRAM) |
| AR (1) | AR098647A1 (OSRAM) |
| AU (1) | AU2014360455B2 (OSRAM) |
| BR (1) | BR112016012844B1 (OSRAM) |
| CA (1) | CA2932729C (OSRAM) |
| CL (1) | CL2016001368A1 (OSRAM) |
| CR (1) | CR20160309A (OSRAM) |
| EA (1) | EA031243B1 (OSRAM) |
| IL (1) | IL246017B (OSRAM) |
| MA (1) | MA39170B1 (OSRAM) |
| MX (1) | MX368443B (OSRAM) |
| MY (1) | MY176049A (OSRAM) |
| PE (1) | PE20160886A1 (OSRAM) |
| PH (1) | PH12016501071B1 (OSRAM) |
| SG (1) | SG11201604573WA (OSRAM) |
| TW (1) | TWI557126B (OSRAM) |
| UA (1) | UA120506C2 (OSRAM) |
| WO (1) | WO2015085007A1 (OSRAM) |
| ZA (1) | ZA201604461B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015004615A (es) | 2012-10-16 | 2015-07-17 | Hoffmann La Roche | Inhibidores de serina/treonina cinasa. |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| JP6449293B2 (ja) | 2013-12-06 | 2019-01-09 | ジェネンテック， インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| WO2015103133A1 (en) | 2013-12-30 | 2015-07-09 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| EP3089980B1 (en) * | 2013-12-30 | 2018-01-31 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
| SI3374359T1 (sl) | 2015-11-09 | 2020-04-30 | Astrazeneca Ab | Derivati dihidroimidazopirazinona uporabni pri zdravljenju raka |
| WO2017180581A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| EP3679159A1 (en) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| WO2019158579A1 (en) | 2018-02-13 | 2019-08-22 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| TWI879771B (zh) * | 2019-06-06 | 2025-04-11 | 大陸商和記黃埔醫藥（上海）有限公司 | 三環類化合物及其用途 |
| AU2022217309A1 (en) * | 2021-02-03 | 2023-09-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused tricyclic cyclin-dependent kinase inhibitor, and preparation method therefor and pharmaceutical use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1438027A1 (en) * | 2001-10-25 | 2004-07-21 | DepoMed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| CN101304973A (zh) * | 2005-09-15 | 2008-11-12 | 佩因赛普托药物公司 | 调节神经营养蛋白介导的活性的方法 |
| US8513276B2 (en) | 2006-12-22 | 2013-08-20 | Astex Therapeutics Limited | Imidazo[1,2-a]pyridine compounds for use in treating cancer |
| EP2002836B1 (en) * | 2007-05-31 | 2010-10-20 | Nerviano Medical Sciences S.r.l. | Cyclocondensed azaindoles active as kinase inhibitors |
| AU2011332043C1 (en) | 2010-11-23 | 2016-11-10 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
| CA2828478C (en) | 2011-02-28 | 2019-12-31 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| WO2013020062A1 (en) | 2011-08-04 | 2013-02-07 | Array Biopharma Inc. | Quinazoline compounds as serine/threonine kinase inhibitors |
| AU2013225737B2 (en) | 2012-03-01 | 2018-03-01 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| BR112015004548A2 (pt) | 2012-08-27 | 2017-08-08 | Array Biopharma Inc | inibidores de serina/treonina para tratamento de doenças hiperproliferativas |
| MX2015004615A (es) | 2012-10-16 | 2015-07-17 | Hoffmann La Roche | Inhibidores de serina/treonina cinasa. |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| JP6449293B2 (ja) | 2013-12-06 | 2019-01-09 | ジェネンテック， インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| EP3089980B1 (en) | 2013-12-30 | 2018-01-31 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
| WO2015103133A1 (en) | 2013-12-30 | 2015-07-09 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| PL3129025T3 (pl) | 2014-04-09 | 2019-11-29 | Genentech Inc | Sposób wytwarzania środków leczniczych |
-
2014
- 2014-12-03 JP JP2016536560A patent/JP6449293B2/ja active Active
- 2014-12-03 BR BR112016012844-3A patent/BR112016012844B1/pt not_active IP Right Cessation
- 2014-12-03 US US14/559,786 patent/US9867833B2/en active Active
- 2014-12-03 KR KR1020167017847A patent/KR102359759B1/ko not_active Expired - Fee Related
- 2014-12-03 CA CA2932729A patent/CA2932729C/en active Active
- 2014-12-03 PE PE2016000741A patent/PE20160886A1/es unknown
- 2014-12-03 UA UAA201607281A patent/UA120506C2/uk unknown
- 2014-12-03 WO PCT/US2014/068452 patent/WO2015085007A1/en not_active Ceased
- 2014-12-03 EP EP14827591.0A patent/EP3077401B1/en active Active
- 2014-12-03 EA EA201691177A patent/EA031243B1/ru not_active IP Right Cessation
- 2014-12-03 CR CR20160309A patent/CR20160309A/es unknown
- 2014-12-03 MA MA39170A patent/MA39170B1/fr unknown
- 2014-12-03 AU AU2014360455A patent/AU2014360455B2/en not_active Ceased
- 2014-12-03 SG SG11201604573WA patent/SG11201604573WA/en unknown
- 2014-12-03 CN CN201480074890.9A patent/CN106029672B/zh active Active
- 2014-12-03 MY MYPI2016001051A patent/MY176049A/en unknown
- 2014-12-03 MX MX2016007352A patent/MX368443B/es active IP Right Grant
- 2014-12-05 AR ARP140104549A patent/AR098647A1/es unknown
- 2014-12-05 TW TW103142501A patent/TWI557126B/zh not_active IP Right Cessation
-
2016
- 2016-06-03 CL CL2016001368A patent/CL2016001368A1/es unknown
- 2016-06-05 IL IL24601716A patent/IL246017B/en active IP Right Grant
- 2016-06-06 PH PH12016501071A patent/PH12016501071B1/en unknown
- 2016-06-30 ZA ZA2016/04461A patent/ZA201604461B/en unknown
-
2017
- 2017-09-14 US US15/705,104 patent/US10278975B2/en active Active
-
2018
- 2018-11-09 JP JP2018211421A patent/JP2019034970A/ja active Pending
-
2019
- 2019-02-27 US US16/286,955 patent/US10517878B2/en active Active
- 2019-11-11 US US16/680,221 patent/US10842799B2/en active Active
-
2020
- 2020-10-20 US US17/075,380 patent/US11376260B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001368A1 (es) | Inhibidores de cinasa serina/treonina | |
| CL2015002151A1 (es) | Biaril amide compuestos como inhibidores de quinasa | |
| CL2019000542A1 (es) | Compuestos de tetraciclina y métodos de uso de los mismos. | |
| CO2018008761A2 (es) | Derivados de maitansinoide, conjugados de los mismos métodos de uso | |
| CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
| CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
| CL2016000925A1 (es) | Inhibidores de bromodominio | |
| BR112015032718A2 (pt) | composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| CL2015002194A1 (es) | Inhbidores de erk y sus usos | |
| CL2015001733A1 (es) | Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer. | |
| MX369863B (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2015003735A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| CL2016001537A1 (es) | Inhibidores de syk | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| CL2013002430A1 (es) | Compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de proteina kinasa trk; composicion farmaceutica; compuesto intermediarios; utiles para el tratamiento de carcinoma pailar de tiroides, cancer de pancreas, cancer de colon y carcinoma de mama, entre otras. | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| MX2015015421A (es) | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. | |
| JO3433B1 (ar) | حلقة كاربوكسامايد ذات أربع أعضاء للاستخدام كمبيدات النيماتودا | |
| MX2015015417A (es) | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. | |
| CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| EA201591960A1 (ru) | Ингибиторы акк и их применение |